메뉴 건너뛰기




Volumn 502, Issue , 2012, Pages 123-138

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues

Author keywords

Antibody reduction; Antibody drug conjugates; Conjugation strategies; Drug loading; Maleimido drug linker; Unconjugated drug content

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CYSTEINE;

EID: 84855379223     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416039-2.00006-9     Document Type: Chapter
Times cited : (95)

References (21)
  • 2
    • 38949192547 scopus 로고    scopus 로고
    • Targeted cancer therapy: Conferring specificity to cytotoxic drugs
    • R.V. Chari Targeted cancer therapy: Conferring specificity to cytotoxic drugs Acc. Chem. Res. 41 2008 98 107
    • (2008) Acc. Chem. Res. , vol.41 , pp. 98-107
    • Chari, R.V.1
  • 6
    • 74949139946 scopus 로고    scopus 로고
    • Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
    • H.K. Erickson Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
    • (2010) Bioconjug. Chem. , vol.21 , pp. 84-92
    • Erickson, H.K.1
  • 8
    • 49449087300 scopus 로고    scopus 로고
    • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    • J.R. Junutula Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
    • (2008) Nat. Biotechnol. , vol.26 , pp. 925-932
    • Junutula, J.R.1
  • 9
    • 77957590621 scopus 로고    scopus 로고
    • Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
    • J.R. Junutula Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16 2010 4769 4778
    • (2010) Clin. Cancer Res. , vol.16 , pp. 4769-4778
    • Junutula, J.R.1
  • 10
    • 78651360674 scopus 로고    scopus 로고
    • Optimizing therapeutic antibody function: Progress with Fc domain engineering
    • E. Kaneko, and R. Niwa Optimizing therapeutic antibody function: Progress with Fc domain engineering BioDrugs 25 2011 1 11
    • (2011) BioDrugs , vol.25 , pp. 1-11
    • Kaneko, E.1    Niwa, R.2
  • 13
    • 56449129810 scopus 로고    scopus 로고
    • Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    • G.D. Lewis Phillips Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68 2008 9280 9290
    • (2008) Cancer Res. , vol.68 , pp. 9280-9290
    • Lewis Phillips, G.D.1
  • 15
    • 54049093284 scopus 로고    scopus 로고
    • Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
    • C.F. McDonagh Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
    • (2008) Mol. Cancer Ther. , vol.7 , pp. 2913-2923
    • McDonagh, C.F.1
  • 16
    • 34247876138 scopus 로고    scopus 로고
    • Development trends for monoclonal antibody cancer therapeutics
    • DOI 10.1038/nrd2241, PII NRD2241
    • J.M. Reichert, and V.E. Valge-Archer Development trends for monoclonal antibody cancer therapeutics Nat. Rev. Drug Discov. 6 2007 349 356 (Pubitemid 46696550)
    • (2007) Nature Reviews Drug Discovery , vol.6 , Issue.5 , pp. 349-356
    • Reichert, J.M.1    Valge-Archer, V.E.2
  • 17
    • 67649886201 scopus 로고    scopus 로고
    • Potent antibody drug conjugates for cancer therapy
    • P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 3 2009 235 244
    • (2009) Curr. Opin. Chem. Biol. , vol.13 , Issue.3 , pp. 235-244
    • Senter, P.D.1
  • 18
    • 64949125849 scopus 로고    scopus 로고
    • Antibody-cytotoxic agent conjugates: Preparation and characterization
    • (xiv)
    • R. Singh, and H.K. Erickson Antibody-cytotoxic agent conjugates: Preparation and characterization Methods Mol. Biol. 525 2009 445 467 (xiv)
    • (2009) Methods Mol. Biol. , vol.525 , pp. 445-467
    • Singh, R.1    Erickson, H.K.2
  • 21
    • 78049515807 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    • A. Younes Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1812-1821
    • Younes, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.